Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
Michael Ka-Shing CheungHo Yu NgRex Wan Hin HuiLok Ka LamLoey Lung-Yi MakYuen Chi HoJing Tong TanEsther W ChanWai Kay SetoMan Fung YuenWai-Keung LeungPublished in: Hepatology (Baltimore, Md.) (2024)
Empagliflozin for 52 weeks reduces hepatic fat content in subjects with nondiabetic metabolic dysfunction-associated steatotic liver disease. (ClinicalTrials.gov Identifier: NCT04642261).